Evidence map›Paper›PMID 31934177›Full record

ArticleInternational journal of clinical and experimental pathology2019

Screening of the copy number increase of

Kentaro Minegishi, Yoh Dobashi, Hiroyoshi Tsubochi, Ryoko Tokuda, Koji Okudela, Akishi Ooi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Prognostic impact ofNeuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Kentaro MinegishiDepartment of Thoracic Surgery, Saitama Medical Center, Jichi Medical University 1-847 Amanuma, Omiya, Saitama 330-8503, Japan.
Yoh DobashiDepartment of Pathology, Saitama Medical Center, Jichi Medical University 1-847 Amanuma, Omiya, Saitama 330-8503, Japan.
Hiroyoshi TsubochiDepartment of Thoracic Surgery, Saitama Medical Center, Jichi Medical University 1-847 Amanuma, Omiya, Saitama 330-8503, Japan.
Ryoko TokudaDepartment of Molecular and Cellular Pathology, Kanazawa University Graduate School of Medical Science Kanazawa, Japan.
Koji OkudelaDepartment of Pathology, Yokohama City University Graduate School of Medicine Yokohama, Kanagawa, Japan.
Akishi OoiDepartment of Molecular and Cellular Pathology, Kanazawa University Graduate School of Medical Science Kanazawa, Japan.
Jichi Medical University · JPKanazawa University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatments for lung cancer include therapies targeting aberrant oncoproteins, but there remains a high medical need for novel therapies. Our previous studies showed that gene amplification/high-level polysomy of

Indexed as

AKTFISHgene increaselung cancerMLPA

Identifiers

PMID31934177
PMCPMC6949816
OpenAlexW3005920331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.